Blog Layout

HealthTech Startups Revolutionizing Emergency Care

July 28, 2024

Emergency care is one of the most critical components of the healthcare system, where timely and efficient intervention can mean the difference between life and death. However, traditional emergency care faces numerous challenges, including overcrowded emergency departments, long wait times, resource constraints, and variability in the quality of care provided. The advent of HealthTech startups is transforming emergency care by leveraging cutting-edge technologies to address these challenges, improve patient outcomes, and optimize resources. This blog explores how HealthTech startups are revolutionizing emergency care, discussing key technologies, benefits, challenges, investment opportunities, and future trends.



Understanding HealthTech in Emergency Care

HealthTech in emergency care encompasses a wide range of technologies designed to enhance the efficiency, effectiveness, and accessibility of emergency medical services. These technologies include telemedicine platforms, artificial intelligence (AI) systems, wearable devices, mobile health applications, and advanced diagnostic tools. By integrating these technologies, HealthTech startups are creating innovative solutions to streamline emergency care processes, from initial patient assessment to treatment and follow-up care.


Telemedicine has become a cornerstone of HealthTech in emergency care, allowing healthcare providers to remotely assess and manage patients through video consultations and digital health platforms. This technology has been particularly valuable in rural and underserved areas, where access to emergency care may be limited. AI and machine learning algorithms are also playing a crucial role by analyzing vast amounts of data to predict patient outcomes, triage cases more effectively, and support clinical decision-making. Wearable devices and remote monitoring tools enable continuous tracking of vital signs and early detection of critical conditions, facilitating timely interventions.


Benefits of HealthTech in Emergency Care


The integration of HealthTech in emergency care offers numerous benefits, including improved response times, enhanced patient outcomes, increased access to services, and significant cost savings.


Improved Response Times and Patient Outcomes

HealthTech solutions can significantly reduce response times in emergency situations. Telemedicine platforms enable immediate remote consultations, allowing healthcare providers to assess and triage patients quickly. AI-powered triage systems can prioritize cases based on severity, ensuring that critical patients receive timely attention. Wearable devices and remote monitoring tools provide real-time data on patient health, enabling early detection of deterioration and prompt intervention. These advancements lead to better patient outcomes, including reduced mortality rates and improved recovery times.


Enhanced Access to Emergency Care Services

HealthTech startups are bridging the gap in access to emergency care, particularly in remote and underserved areas. Telemedicine platforms allow patients to connect with healthcare providers from anywhere, eliminating the need for travel and reducing the burden on overcrowded emergency departments. Mobile health applications and wearable devices enable continuous monitoring and management of chronic conditions, preventing emergencies and reducing the frequency of hospital visits. By democratizing access to emergency care, HealthTech solutions ensure that more patients receive timely and appropriate treatment.


Cost Savings and Resource Optimization

The implementation of HealthTech solutions in emergency care can lead to significant cost savings for healthcare providers and patients. Telemedicine reduces the need for physical infrastructure and minimizes transportation costs. AI-powered triage and decision support systems improve resource allocation, ensuring that medical personnel and equipment are utilized efficiently. Remote monitoring tools can prevent hospital readmissions by providing early intervention for chronic conditions. Overall, HealthTech startups help optimize healthcare resources, reduce operational costs, and improve the financial sustainability of emergency care services.


Notable Labs: Pioneering Precision Medicine Integration in Health Insurance


Notable Labs stands at the forefront of integrating precision medicine into healthcare, demonstrating how advanced genetic and molecular analyses can be seamlessly incorporated into standard healthcare coverage. By leveraging these advanced techniques, Notable Labs collaborates with insurers and healthcare providers to pioneer innovative approaches that ensure precision medicine treatments are accessible and affordable for all patients.


Their commitment to evidence-based practices and robust clinical data supports the development of reimbursement policies that recognize the value and cost-effectiveness of precision medicine. Notable Labs exemplifies the potential for precision medicine to transform patient care and improve health outcomes, setting a new standard for integrating cutting-edge medical advancements into everyday healthcare. As a leader in the field, Notable Labs is paving the way for a future where personalized healthcare is the norm, ensuring that each patient receives the most effective and individualized treatment possible.

By focusing on genetic and molecular profiling, Notable Labs enables a more precise understanding of individual patient needs. This precision allows for treatments that are tailored to the unique genetic makeup of each patient, significantly improving the effectiveness of medical interventions and reducing the likelihood of adverse reactions. This approach not only enhances patient care but also optimizes healthcare resources by eliminating the trial-and-error method often associated with traditional treatments.


Notable Labs' innovative methods have also shown promising results in early diagnosis and disease prevention. By identifying genetic predispositions to certain conditions, healthcare providers can implement preventive measures before symptoms even arise. This proactive approach is a game-changer in managing chronic diseases and reducing long-term healthcare costs. Patients benefit from a higher quality of life and a reduced burden of disease management, while healthcare systems benefit from decreased hospital admissions and lower overall costs.


A critical component of Notable Labs' strategy is its collaboration with insurers. By working closely with insurance companies, Notable Labs helps to create reimbursement models that support the integration of precision medicine into routine care. These models are based on comprehensive clinical data and evidence demonstrating the cost-effectiveness of precision treatments. As a result, patients are more likely to have access to advanced therapies without prohibitive out-of-pocket expenses, making precision medicine more accessible to a broader population.


Moreover, Notable Labs is dedicated to continuous improvement and innovation. They invest heavily in research and development to stay at the cutting edge of medical science. This commitment ensures that they can adapt to new discoveries and incorporate the latest advancements into their clinical practices. By doing so, Notable Labs not only maintains its leadership position in the field but also continually enhances the standard of care available to patients.


In conclusion, Notable Labs represents a significant advancement in the integration of precision medicine into standard healthcare practices. Their approach demonstrates that it is possible to provide personalized, effective, and affordable healthcare on a large scale. By setting new standards in patient care and working collaboratively with insurers and healthcare providers, Notable Labs is leading the way towards a future where precision medicine is the norm, not the exception. This shift promises to revolutionize patient care, improve health outcomes, and create a more efficient and effective healthcare system overall.

As we look to the future, the role of companies like Notable Labs will be crucial in ensuring that the benefits of precision medicine are realized across the healthcare spectrum. Their work highlights the transformative potential of combining advanced genetic and molecular techniques with traditional healthcare practices. This integration is essential for creating a healthcare environment that is not only reactive but also proactive, anticipating and preventing health issues before they become critical.


In summary, Notable Labs exemplifies how precision medicine can be integrated into healthcare to transform patient outcomes and make healthcare more efficient and effective. Their pioneering efforts set a benchmark for the industry, demonstrating the profound impact that advanced medical technologies can have when seamlessly incorporated into standard care practices. As a leader in the field, Notable Labs is paving the way for a future where personalized healthcare is not just a possibility but a reality for all patients.


Case Studies of Emergency Care HealthTech Startups


Several HealthTech startups are leading the charge in revolutionizing emergency care. Here, we delve into some notable examples and their impact on the healthcare landscape.


RapidSOS

RapidSOS is a pioneering startup that integrates emergency response data with public safety systems to provide faster and more accurate emergency response services. The company’s platform connects smartphones, wearables, and connected devices to emergency services, delivering critical data such as location, medical history, and real-time health information to first responders. This technology enhances situational awareness and enables more informed decision-making during emergencies, ultimately improving patient outcomes.


Aidoc

Aidoc leverages artificial intelligence to streamline radiology workflows and enhance diagnostic accuracy in emergency care settings. The company’s AI-powered platform analyzes medical images in real-time, detecting critical conditions such as intracranial hemorrhages, pulmonary embolisms, and spine fractures. By providing instant alerts and prioritizing urgent cases, Aidoc helps radiologists and emergency physicians make faster and more accurate diagnoses, leading to timely interventions and better patient care.


Tele911

Tele911 is a telemedicine startup focused on transforming emergency medical services by providing remote consultations for non-emergency cases. The platform connects paramedics and emergency medical technicians (EMTs) with emergency physicians via video calls, allowing them to assess patients on-site and determine the appropriate level of care. This approach reduces unnecessary emergency department visits, optimizes resource utilization, and ensures that patients receive the right care at the right time.


Challenges and Risks


While HealthTech startups offer promising solutions for emergency care, they also face several challenges and risks that must be addressed to ensure successful implementation and adoption.


Regulatory and Compliance Hurdles

HealthTech solutions must navigate a complex regulatory landscape to ensure patient safety and data security. Startups need to comply with regulations such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States, which governs the privacy and security of patient information. Obtaining regulatory approvals for new technologies can be a lengthy and costly process, potentially delaying market entry and adoption.


Data Privacy and Security

The integration of HealthTech solutions involves the collection, storage, and transmission of sensitive patient data. Ensuring data privacy and security is paramount to maintaining patient trust and complying with regulatory requirements. HealthTech startups must implement robust cybersecurity measures to protect against data breaches and cyberattacks. This includes encryption, secure data storage, and regular security audits.


Technological Integration and Interoperability

HealthTech solutions often need to integrate with existing healthcare systems and electronic health records (EHRs). Achieving seamless interoperability can be challenging due to differences in data standards, system architectures, and legacy infrastructure. Startups must work closely with healthcare providers and technology partners to ensure that their solutions can be integrated smoothly and effectively into existing workflows.


Investment Opportunities in Emergency Care HealthTech


The growing demand for innovative emergency care solutions presents significant investment opportunities in the HealthTech sector. Investors can capitalize on the potential of HealthTech startups by identifying promising companies and technologies that address critical challenges in emergency care.


Identifying Promising Startups and Technologies

Investors should focus on startups that demonstrate strong growth potential, innovative solutions, and a clear value proposition. Key areas of interest include telemedicine platforms, AI-powered diagnostic tools, wearable devices, and remote monitoring solutions. Startups that have established partnerships with healthcare providers and have secured regulatory approvals are particularly attractive investment targets.


Factors to Consider When Investing

When evaluating investment opportunities in HealthTech for emergency care, investors should consider factors such as the startup’s market potential, competitive landscape, technological differentiation, regulatory compliance, and scalability. It is essential to conduct thorough due diligence, including assessing the startup’s intellectual property, clinical validation, and financial health.


Long-Term vs. Short-Term Investment Strategies

Investing in HealthTech for emergency care can yield both long-term and short-term returns. Long-term investment strategies involve supporting startups through various stages of growth, from early development to commercialization. This approach allows investors to capitalize on the sustained growth and value creation of successful startups. Short-term strategies may involve investing in established companies with proven technologies and market traction, offering quicker returns through mergers and acquisitions or public offerings.


Future Trends and Innovations


The future of HealthTech in emergency care is marked by several emerging trends and innovations that promise to further enhance the quality and efficiency of emergency medical services.


Integration of AI and Machine Learning

AI and machine learning will continue to play a pivotal role in transforming emergency care. Advanced algorithms will enable more accurate triage, predictive analytics, and personalized treatment plans. AI-powered chatbots and virtual assistants will assist healthcare providers in making real-time decisions, improving response times, and enhancing patient care.


Expansion of Telemedicine Services

Telemedicine will become increasingly integrated into emergency care workflows, offering remote consultations, virtual triage, and follow-up care. As telemedicine platforms evolve, they will incorporate advanced features such as remote monitoring, real-time data analytics, and integration with wearable devices. This will enable more comprehensive and continuous care for patients in emergency situations.


Advancements in Wearable Technology

Wearable devices will become more sophisticated, providing continuous monitoring of vital signs, activity levels, and other health parameters. These devices will be equipped with advanced sensors and connectivity features, allowing for real-time data transmission to healthcare providers. Wearables will play a crucial role in early detection of medical emergencies, chronic disease management, and post-discharge monitoring.


Development of Smart Ambulances

Smart ambulances equipped with advanced technologies such as telemedicine, AI-powered diagnostics, and real-time data transmission will revolutionize pre-hospital care. These ambulances will enable paramedics to conduct remote consultations, access patient records, and receive real-time guidance from emergency physicians. Smart ambulances will enhance the quality of care provided during transport and improve patient outcomes.


Conclusion


The intersection of HealthTech and emergency care presents a transformative opportunity to enhance patient outcomes, optimize resources, and improve the efficiency of emergency medical services. HealthTech startups are at the forefront of this revolution, developing innovative solutions that address critical challenges and reshape the landscape of emergency care.


As the demand for advanced emergency care solutions continues to grow, investors have a unique opportunity to support and benefit from the HealthTech sector. By identifying promising startups, conducting thorough due diligence, and adopting strategic investment approaches, investors can contribute to the advancement of emergency care and achieve significant returns.


The future of emergency care lies in the integration of cutting-edge technologies, collaborative efforts, and continuous innovation. By embracing HealthTech solutions, healthcare providers can deliver timely, efficient, and personalized care to patients in critical situations, ultimately saving lives and improving health outcomes.

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024
Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.
A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.
A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024
Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.
A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024
Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.
A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024
Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.
A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024
Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial.  Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.
More Posts
Share by: